Art. -Nr.: HY-50752

LY-411575

29 Cited Publications

Kundenbewertung

Based on 29 publication(s) in Google Scholar

LY-411575 is a potent γ-secretase inhibitor with IC₅₀ of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC₅₀ of 0.39 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.28%
CAS. Nr.: 209984-57-6
Formel: C₂₆H₂₃F₂N₃O₄
Molecular Weight:479.48

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

LY-411575 Chemical Structure

CAS. Nr.: 209984-57-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (29)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

LY-411575 is a potent γ-secretase inhibitor with IC₅₀ of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC₅₀ of 0.39 nM.

IC₅₀ & Target

IC50: 0.078 nM (γ-secretase in membrane), 0.082 nM (γ-secretase cell-based), 0.39 nM (Notch S3 cleavage cell-based)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	114 pM Compound: LY-411575	Reduction of human wild type PS1-induced amyloid beta-40 level in CHO cells overexpressing human APP751 after 24 hrs by liquid phase electrochemiluminescence assay relative to control Reduction of human wild type PS1-induced amyloid beta-40 level in CHO cells overexpressing human APP751 after 24 hrs by liquid phase electrochemiluminescence assay relative to control	[PMID: 17573346]
CHO	EC₅₀	135 pM Compound: LY-411575	Reduction of human wild type PS1-induced amyloid beta-42 level in CHO cells overexpressing human APP751 after 24 hrs by liquid phase electrochemiluminescence assay relative to control Reduction of human wild type PS1-induced amyloid beta-42 level in CHO cells overexpressing human APP751 after 24 hrs by liquid phase electrochemiluminescence assay relative to control	[PMID: 17573346]
CHO	EC₅₀	352 pM Compound: LY-411575	Reduction of human PS1 delta exon9 mutant-induced amyloid beta-42 level in CHO cells overexpressing human APP751after 24 hrs by liquid phase electrochemiluminescence assay relative to control Reduction of human PS1 delta exon9 mutant-induced amyloid beta-42 level in CHO cells overexpressing human APP751after 24 hrs by liquid phase electrochemiluminescence assay relative to control	[PMID: 17573346]
CHO	EC₅₀	358 pM Compound: LY-411575	Reduction of human PS1 delta exon9 mutant-induced amyloid beta-40 level in CHO cells overexpressing human APP751after 24 hrs by liquid phase electrochemiluminescence assay relative to control Reduction of human PS1 delta exon9 mutant-induced amyloid beta-40 level in CHO cells overexpressing human APP751after 24 hrs by liquid phase electrochemiluminescence assay relative to control	[PMID: 17573346]
HEK293	EC₅₀	119 pM Compound: LY-411575	Inhibition of gamma secretase in human HEK293 cells assessed as amyloid beta 40 production Inhibition of gamma secretase in human HEK293 cells assessed as amyloid beta 40 production	[PMID: 17573346]
HEK293	IC₅₀	1.2 μM Compound: LY411575	Modulation of gamma-secretase in HEK293 cells expressing guinea pig Swedish mutant SFV-APP695sw coexpressing DLL4 assessed as inhibition of notch processing in human TE671 cells after 3 days by dual-cell luciferase reporter gene assay Modulation of gamma-secretase in HEK293 cells expressing guinea pig Swedish mutant SFV-APP695sw coexpressing DLL4 assessed as inhibition of notch processing in human TE671 cells after 3 days by dual-cell luciferase reporter gene assay	[PMID: 24139583]
HEK293	IC₅₀	0.08 nM Compound: 19; LY-411575	Inhibition of gamma secretase in HEK293 cells expressing APP 695 assessed as reduction in amyloid beta levels after 5 hrs by Western blot analysis Inhibition of gamma secretase in HEK293 cells expressing APP 695 assessed as reduction in amyloid beta levels after 5 hrs by Western blot analysis	[PMID: 27045975]
HEK293	IC₅₀	0.39 nM Compound: 19; LY-411575	Inhibition of gamma secretase mediated Notch signaling in HEK293 cells after 5 hrs by Western blot analysis Inhibition of gamma secretase mediated Notch signaling in HEK293 cells after 5 hrs by Western blot analysis	[PMID: 27045975]
HEK293	IC₅₀	0.01 μM Compound: 42; LY-411,575	Inhibition of human SPPL2a expressed in HEK293 cells using GAL4-VP16 fusedTNFalpha (1 to 76)-NTF as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay Inhibition of human SPPL2a expressed in HEK293 cells using GAL4-VP16 fusedTNFalpha (1 to 76)-NTF as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay	[PMID: 29359565]
HEK293	IC₅₀	<0.0003 μM Compound: 42; LY-411,575	Inhibition of human gamma-secretase expressed in HEK293 cells using Notch1-VP16-Gal4 as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay Inhibition of human gamma-secretase expressed in HEK293 cells using Notch1-VP16-Gal4 as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay	[PMID: 29359565]
HEK293	IC₅₀	<0.3 nM Compound: 42; LY-411,575	Inhibition of human gamma-secretase expressed in HEK293 cells using Notch1-VP16-Gal4 as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay Inhibition of human gamma-secretase expressed in HEK293 cells using Notch1-VP16-Gal4 as substrate after 24 hrs by Bright-Glo luciferase reporter gene assay	[PMID: 29359565]
Huh-7	IC₅₀	80 μM Compound: 118, LY-411575	Antimalarial activity against Plasmodium berghei ANKA infected in human Huh7 cells after 24 hrs by qRT-PCR Antimalarial activity against Plasmodium berghei ANKA infected in human Huh7 cells after 24 hrs by qRT-PCR	[PMID: 22122518]
SH-SY5Y	IC₅₀	1 nM Compound: 15 LY-411575	Displacement of [3H]5-chloro-N-((2S,3R)-5,5,5-trifluoro-1-hydroxy-3-methylpentan-2-yl)thiophene-2-sulfonamide from gamma secretase in human SH-SY5Y cells by competitive binding assay Displacement of [3H]5-chloro-N-((2S,3R)-5,5,5-trifluoro-1-hydroxy-3-methylpentan-2-yl)thiophene-2-sulfonamide from gamma secretase in human SH-SY5Y cells by competitive binding assay	[PMID: 19694467]
SH-SY5Y	IC₅₀	1 nM Compound: 15 LY-411575	Inhibition of gamma secretase-mediated amyloid beta (1 to 40) production in human SH-SY5Y cells Inhibition of gamma secretase-mediated amyloid beta (1 to 40) production in human SH-SY5Y cells	[PMID: 19694467]

In Vitro

LY-411575 blocks Notch activation, and results in apoptosis in primary and immortalized KS cells. LY-411,575 (500 μM) induces G2/M growth arrest SLK cells^[2].
LY411575 treatment significantly decreases the amounts of intracellular HCV RNA with IC₅₀ of 0.56?±?0.20?μM and extracellular HCV particles. LY411575 (0-40?nM) alone or in combination with BMS-790052 (0-40?pM) decreases supernatant infectious titers in a dose-dependent manner, and is synergistic regarding production of infectious virus. LY411575 (10?μM) treatment impairs ROS production in HCVcc-infected cells^[4]. LY411575 significantly attenuates EMT by inhibiting the Notch signaling activation in vitro^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

LY-411,575 (10 mg/kg) decreases brain and plasma Aβ40 and -42 robustly when chronically administered to TgCRND8 mice^[1]. LY411,575 reduces cortical Aβ40 in young transgenic CRND8 mice (ED₅₀ appr 0.6 mg/kg) and produces significant thymus atrophy and intestinal goblet cell hyperplasia at higher doses (>3 mg/kg). The extent of intestinal goblet cell hyperplasia induced by LY411,575 (10 mg/kg) is similar in young and aged mice^[3]. LY411575 inhibits mouse proliferative vitreoretinopathy (PVR) formation in vivo^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 209984-57-6
Appearance Solid
Molecular Weight 479.48
Formel C₂₆H₂₃F₂N₃O₄
Color White to off-white
SMILES

O=C1[C@@H](NC([C@@H](NC([C@H](C2=CC(F)=CC(F)=C2)O)=O)C)=O)C3=CC=CC=C3C(C=CC=C4)=C4N1C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (29)

All IFWB

Sort by:

Journal Impact Factor

Nat Commun

Notch coordinates self-organization of germ layers and axial polarity in sea anemone gastruloids. [Abstract]

2026 Jun 19. PMID: 42321198
Nat Commun

Segregation of endoderm and mesoderm germ layer identities in the diploblast Nematostella vectensis. [Abstract]

2025 Aug 27;16(1):7979. PMID: 40858588
Adv Sci (Weinh)

Ti3 C2 Tx MXene Composite 3D Hydrogel Potentiates mTOR Signaling to Promote the Generation of Functional Hair Cells in Cochlea Organoids. [Abstract]

2022 Sep 18;e2203557. PMID: 36117048
Cell Death Dis

The histone methyltransferase DOT1L is a new epigenetic regulator of pulmonary fibrosis. [Abstract]

2022 Jan 17;13(1):60. PMID: 35039472
Proc Natl Acad Sci U S A

Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses. [Abstract]

2025 Feb 25;122(8):e2421573122. PMID: 39969998
Cell Rep

In Vivo Visualization of Cardiomyocyte Apicobasal Polarity Reveals Epithelial to Mesenchymal-like Transition during Cardiac Trabeculation. [Abstract]

2016 Dec 6;17(10):2687-2699. PMID: 27926871
Oncoimmunology

Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer. [Abstract]

2018 Aug 23;7(11):e1461303. PMID: 30377557

LY-411575 purchased from MedChemExpress. Usage Cited in: Oncoimmunology. 2018 Aug 23;7(11):e1461303. [Abstract]

The expression of Oct4 in A549 and H460 cells treated with or without rhIL-17A and these molecular inhibitors (NF-kB inhibitor: PDAC, Notch1 inhibitor: LY411575) are assessed by western blotting.
Chin J Nat Med

Luteolin ameliorates ulcerative colitis in mice via reducing the depletion of NCR+ILC3 through Notch signaling pathway. [Abstract]

2024 Nov;22(11):991-1002. PMID: 39510641
Int Immunopharmacol

Luteolin alleviates ulcerative colitis by restoring the balance of NCR-ILC3/NCR+ILC3 to repairing impaired intestinal barrier. [Abstract]

2022 Sep 28;112:109251. PMID: 36182875
Molecules

New flurbiprofen derivatives: synthesis, membrane affinity and evaluation of in vitro effect on β-amyloid levels. [Abstract]

2013 Sep 3;18(9):10747-67. PMID: 24005968
BMC Biol

Progenitor potential of nkx6.1-expressing cells throughout zebrafish life and during beta cell regeneration. [Abstract]

2015 Sep 2;13(1):70. PMID: 26329351

LY-411575 purchased from MedChemExpress. Usage Cited in: BMC Biol. 2015 Sep 2;13(1):70. [Abstract]

Short-term lineage tracing: immunodetection of GFP and the Ins and Gcg hormones in 5-dpf Tg(ascl1b:eGFP-creER ^T2 ) embryos treated from 3 to 5 dpf with DMSO or with the Notch signaling inhibitor, LY411575.
BMC Biol

Ascl1b and Neurod1, instead of Neurog3, control pancreatic endocrine cell fate in zebrafish. [Abstract]

2013 Jul 8;11:78. PMID: 23835295
J Virol

SRCAP is involved in porcine reproductive and respiratory syndrome virus activated Notch signaling pathway. [Abstract]

2024 Nov 12:e0121624. PMID: 39530666
Mol Biol Rep

17β-estradiol inhibits Notch1 activation in murine macrophage cell line RAW 264.7. [Abstract]

2024 Nov 8;51(1):1134. PMID: 39514048
J Steroid Biochem Mol Biol

Segetalin B promotes bone formation in ovariectomized mice by activating PLD1/SIRT1 signaling to inhibit γ-secretase-mediated Notch1 overactivation. [Abstract]

2025 Mar:247:106669. PMID: 39736459
Biochem Biophys Res Commun

Establishment of γ-secretase-deficient goblet-like cells: A novel in vitro platform to dissect regulatory mechanisms of mucus production in the intestinal epithelium. [Abstract]

2025 Dec 2:794:153091. PMID: 41344214
Exp Neurobiol

Notch Signaling Controls Oligodendrocyte Regeneration in the Injured Telencephalon of Adult Zebrafish. [Abstract]

2020 Dec 31;29(6):417-424. PMID: 33281119
J Vis Exp

2026 Apr 3:(230). PMID: 42008371
bioRxiv

2025 Sep 9.
bioRxiv

2025 Aug 12.
bioRxiv

Tnfrsf10 Signaling is Required to Maintain the Stem Cell Niche in the Zebrafish Lateral Line. [Abstract]

2025 Apr 19:2025.04.18.649014. PMID: 40568085
Res Sq

2025 Feb 23.
bioRxiv

2025 January 09.
bioRxiv

2024 October 29.
bioRxiv

2023 Jun 12.
Curr Res Pharmacol Drug Discov

Jagged-1 is induced by mTOR inhibitors in renal cancer cells through an Akt/ALK5/Smad4-dependent mechanism. [Abstract]

2022 Jul 4:3:100117. PMID: 35992379
ACS Comb Sci

Benzimidazolyl-pyrazolo[3,4- b]pyridinones, Selective Inhibitors of MOLT-4 Leukemia Cell Growth and Sea Urchin Embryo Spiculogenesis: Target Quest. [Abstract]

2019 Dec 9;21(12):805-816. PMID: 31689077
Goethe University

2019 Dec.
University of Liege

Septembre. 2015.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (208.56 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0856 mL

10.4280 mL

20.8559 mL

5 mM

0.4171 mL

2.0856 mL

4.1712 mL

10 mM

0.2086 mL

1.0428 mL

2.0856 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.21 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Animal Administration^[3]

Mice from the aged cohort (16-26 months old) are either retired breeders or experimentally naive mice. Before dosing begin and for the duration of the study, mice are singly housed with a plastic igloo and nesting material. Mice are sacrificed 2 to 4 h after their final dosing. For oral dosing, LY411,575 and LY-D are formulated as 10 mg/mL solutions and diluted 1:10 with 0.4% methycellulose. In the case of subcutaneous dosing, the 10 mg/mL stock solution is diluted 1:10 with 20% hydroxyl-propyl-β-cyclodextrin. If necessary, serial dilutions are made from the 1 mg/mL solution using the appropriate 1:10 vehicle. The dosing volume is 10 mL/kg. After oral administration of 10 mg/kg LY411,575, inhibition of plasma Aβ is still significant 24, but not 48, h after dosing, so in an effort to maintain continuous γ-secretase inhibition, LY411,575 and LY-D are dosed once per day in all studies.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wong GT, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004 Mar 26;279(13):12876-82. [Content Brief]

[2]. Otoguro T, et al. Inhibitory effect of presenilin inhibitor LY411575 on maturation of hepatitis C virus core protein, production of the viral particle and expression of host proteins involved in pathogenicity. Microbiol Immunol. 2016 Nov;60(11):740-753 [Content Brief]

[3]. Curry CL, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005 Sep 22;24(42):6333-44. [Content Brief]

[4]. Zhang J, et al. Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. Histochem Cell Biol. 2017 Mar;147(3):367-375. [Content Brief]

[5]. Hyde LA, et al. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0856 mL	10.4280 mL	20.8559 mL	52.1398 mL
	5 mM	0.4171 mL	2.0856 mL	4.1712 mL	10.4280 mL
	10 mM	0.2086 mL	1.0428 mL	2.0856 mL	5.2140 mL
	15 mM	0.1390 mL	0.6952 mL	1.3904 mL	3.4760 mL
	20 mM	0.1043 mL	0.5214 mL	1.0428 mL	2.6070 mL
	25 mM	0.0834 mL	0.4171 mL	0.8342 mL	2.0856 mL
	30 mM	0.0695 mL	0.3476 mL	0.6952 mL	1.7380 mL
	40 mM	0.0521 mL	0.2607 mL	0.5214 mL	1.3035 mL
	50 mM	0.0417 mL	0.2086 mL	0.4171 mL	1.0428 mL
	60 mM	0.0348 mL	0.1738 mL	0.3476 mL	0.8690 mL
	80 mM	0.0261 mL	0.1303 mL	0.2607 mL	0.6517 mL
	100 mM	0.0209 mL	0.1043 mL	0.2086 mL	0.5214 mL

Keywords

LY-411575

29 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

LY-411575

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) LY-411575

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LY-411575

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

Stem Cell Signaling Compound Library

Wnt/Hedgehog/Notch Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Publications Citing Use of MedChemExpress (MCE) LY-411575

Biologische Aktivität

Chemical Information

Publications (29)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

LY-411575 Related Classifications

Art. -Nr.: HY-50752